Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
2023 Spotlight
Special Series
Conference Correspondent
ASCO 2023 - Breast Cancer
LBCL 2022 - Year in Review
NSCLC IO 2022 - Midyear Review
ASCO 2022 - Wrap Up
Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Women's Health
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
2023 Spotlight
Special Series
Conference Correspondent
ASCO 2023 - Breast Cancer
LBCL 2022 - Year in Review
NSCLC IO 2022 - Midyear Review
ASCO 2022 - Wrap Up
Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Women's Health
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
By
Yvette Florio Lane
Drug Updates
,
FDA Approvals, News & Updates
,
Multiple Myeloma
,
In the Literature
Web Exclusives
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM).
Read More ›
Page 5 of 5
2
3
4
5
